Treatment Refractory MAC Lung Disease clinical trials at UCSF
1 research study open to eligible people
Treatment refractory MAC lung disease is a lung infection that does not get better with usual treatments. UCSF is running a study to test if an inhaled medicine called Clofazimine can help. This study looks at how safe and effective this new treatment is for patients.
Showing trials for
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
open to eligible people ages 18-85
This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
Fresno, California and other locations
Our lead scientists for Treatment Refractory MAC Lung Disease research studies include Mohamed Fayed, MD, FCCP.